REVOLUMAB: A phase II trial of Nivolumab in recurrent IDH mutant high-grade gliomas.

Novel effective treatments are needed for recurrent IDH mutant high-grade gliomas (IDHm HGGs). The aim of the multicentric, single-arm, phase II REVOLUMAB trial (NCT03925246) was to assess the efficacy and safety of the anti-PD1 Nivolumab in patients with recurrent IDHm HGGs.

Source: European Journal of Cancer - March 21, 2024 Category: Cancer & Oncology Authors: Picca Alberto, Touat Mehdi, Belin Lisa, Gourmelon Carole, Harlay Vincent, Cuzzubbo Stefania, Cohen-Jonathan Moyal Elizabeth, Bronnimann Charlotte, Di Stefano Anna Luisa, Laurent Isaura, Julie Lerond, Carpentier Catherine, Bielle Franck, Ducray Fran çois, Tags: Clinical Trial Source Type: research